T세포 림프종 시장 : 산업 규모, 점유율, 동향, 기회 및 예측, 유형별, 치료법별, 지역별, 경쟁별(2020-2030년)
T-Cell Lymphoma Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type, By Therapy, By Region, & Competition, 2020-2030F
상품코드:1703332
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 182 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
T세포 림프종 세계 시장 규모는 2024년 22억 6,000만 달러로 평가되었고, 예측 기간 동안 꾸준한 성장세를 보이며 2030년까지 연평균 8.62%의 성장률을 보일 것으로 예측됩니다.
T세포 림프종은 비호지킨림프종(NHL)의 하위 집합으로 림프절, 림프관, 비장, 흉선으로 구성된 면역체계의 중요한 구성요소인 림프계에 발생하는 악성 종양입니다. 특히, T세포 림프종은 비정상적인 T-림프구(T세포)에서 발생하는데, T세포는 백혈구의 일종으로 감염된 세포나 비정상적인 세포를 식별하고 제거하는 데 중요한 역할을 합니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
22억 6,000만 달러
시장 규모 : 2030년
37억 2,000만 달러
CAGR : 2025-2030년
8.62%
급성장 부문
화학요법
최대 시장
북미
T세포 림프종의 임상 증상은 아형과 병기에 따라 다릅니다. 일반적인 증상으로는 림프절 종대, 지속적인 발열, 식은땀, 의도하지 않은 체중 감소, 피로감, 피부 T세포 림프종(CTCL)의 경우 피부 이상 등이 있습니다. 진단은 일반적으로 병력 청취, 신체 검사, 임상 검사, 영상 검사(CT 및 PET 스캔 등), 조직 생검을 포함한 다학제적 접근이 필요합니다. 많은 경우, 질병의 아형을 결정하고 치료 전략을 결정하기 위해 분자 및 유전자 검사를 시행하는 경우가 많습니다.
The global T-cell lymphoma market was valued at USD 2.26 billion in 2024 and is projected to experience robust growth over the forecast period, expanding at a CAGR of 8.62% through 2030. T-cell lymphoma is a subset of non-Hodgkin lymphoma (NHL), a malignancy originating in the lymphatic system-a vital component of the immune system comprising lymph nodes, lymphatic vessels, the spleen, and thymus. Specifically, T-cell lymphomas develop from abnormal T lymphocytes (T cells), a type of white blood cell that plays a critical role in identifying and eliminating infected or abnormal cells.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 2.26 Billion
Market Size 2030
USD 3.72 Billion
CAGR 2025-2030
8.62%
Fastest Growing Segment
Chemotherapy
Largest Market
North America
The clinical presentation of T-cell lymphoma varies based on its subtype and disease stage. Common symptoms include enlarged lymph nodes, persistent fever, night sweats, unintended weight loss, fatigue, and, in the case of cutaneous T-cell lymphoma (CTCL), skin abnormalities. Diagnosis typically involves a multidisciplinary approach, including a review of medical history, physical examination, laboratory testing, imaging studies (such as CT or PET scans), and tissue biopsy. In many cases, molecular and genetic testing is employed to determine disease subtype and inform therapeutic strategies.
Key Market Drivers
Rising Incidence and Prevalence of T-Cell Lymphoma
A major driver of market expansion is the increasing global incidence and prevalence of T-cell lymphoma. Though T-cell lymphomas account for only 5-10% of NHL cases in Western markets, they represent a clinically significant segment due to their diverse biological and clinical profiles. Among the most commonly diagnosed subtypes are Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS) and Angioimmunoblastic T-cell Lymphoma (AITL), which continue to attract considerable attention for therapeutic development and commercial investment.
Despite being considered rare, recent epidemiological data suggests a gradual global uptick in T-cell lymphoma diagnoses. This growing disease burden is creating both an urgent medical need and a significant commercial opportunity. As diagnoses rise across various subtypes-including PTCL, CTCL, and AITL-there is an increasing demand for advanced diagnostic technologies, targeted therapies, and long-term disease management solutions. In response, pharmaceutical and biotechnology companies, along with healthcare providers, are investing more heavily in research and development to deliver effective, patient-centric treatment options.
Key Market Challenges
Treatment Resistance
One of the most pressing challenges in the T-cell lymphoma market is treatment resistance, wherein cancer cells exhibit reduced sensitivity or complete non-responsiveness to therapy. This phenomenon complicates disease management and hinders long-term remission. The biological and clinical heterogeneity of T-cell lymphomas makes it particularly difficult to establish uniform treatment protocols, with certain subtypes demonstrating higher resistance levels.
Although therapeutic advancements have been made, the treatment landscape for T-cell lymphoma remains relatively limited compared to other cancers. This scarcity of options becomes particularly problematic when patients develop resistance to frontline therapies. Resistance may be intrinsic-present at diagnosis-or acquired during the treatment course. Understanding the mechanisms behind this resistance is essential to developing personalized and adaptive therapeutic strategies.
Key Market Trends
Enhanced Patient Access to Emerging Therapies
Improving patient access to innovative therapies is an evolving trend in the T-cell lymphoma market. Pharmaceutical companies, in collaboration with regulatory bodies, are increasingly launching early access and compassionate use programs, enabling eligible patients to receive promising treatments prior to full market approval. These initiatives are especially critical for individuals with limited existing options.
Efforts are also being made to secure multi-regional regulatory approvals and pursue label expansions to cover broader patient populations and additional indications. Stakeholders-including patient advocacy organizations, healthcare providers, and policymakers-are working to dismantle barriers to access by addressing cost-related challenges, insurance limitations, and reimbursement policies.
Innovative pricing models and reimbursement frameworks, developed through collaboration among pharmaceutical companies, healthcare systems, and payers, are facilitating greater access while maintaining financial sustainability. Additionally, initiatives to promote clinical trial participation and educate patients on emerging therapies empower individuals to make informed decisions and explore advanced treatment options.
Key Market Players
Acrotech Biopharma Inc.
Affimed GmbH
Bristol-Myers Squibb Company
Shenzhen Chipscreen Biosciences Co., Ltd.
Citius Pharmaceuticals, Inc
DAIICHI SANKYO COMPANY, LIMITED
Eisai Co., Ltd.
Genor Biopharma Co. Ltd
Innate Pharma SA
Digene Pharmaceuticals Co., Ltd.
Report Scope:
In this report, the Global T-Cell Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global T-Cell Lymphoma Market.
Available Customizations:
Global T-Cell Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. T-Cell Lymphoma Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Peripheral {Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, Other}, Lymphoblastic)
5.2.2. By Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, Other)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America T-Cell Lymphoma Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Therapy
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States T-Cell Lymphoma Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Therapy
6.3.2. Canada T-Cell Lymphoma Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Therapy
6.3.3. Mexico T-Cell Lymphoma Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Therapy
7. Europe T-Cell Lymphoma Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Therapy
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany T-Cell Lymphoma Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Therapy
7.3.2. United Kingdom T-Cell Lymphoma Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Therapy
7.3.3. Italy T-Cell Lymphoma Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Therapy
7.3.4. France T-Cell Lymphoma Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Therapy
7.3.5. Spain T-Cell Lymphoma Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Therapy
8. Asia-Pacific T-Cell Lymphoma Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Therapy
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China T-Cell Lymphoma Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Therapy
8.3.2. India T-Cell Lymphoma Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Therapy
8.3.3. Japan T-Cell Lymphoma Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Therapy
8.3.4. South Korea T-Cell Lymphoma Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Therapy
8.3.5. Australia T-Cell Lymphoma Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Therapy
9. South America T-Cell Lymphoma Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Therapy
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil T-Cell Lymphoma Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Therapy
9.3.2. Argentina T-Cell Lymphoma Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Therapy
9.3.3. Colombia T-Cell Lymphoma Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Therapy
10. Middle East and Africa T-Cell Lymphoma Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Therapy
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa T-Cell Lymphoma Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Therapy
10.3.2. Saudi Arabia T-Cell Lymphoma Market Outlook
